Artivion (NYSE:AORT) Hits New 52-Week High at $21.90

Artivion, Inc. (NYSE:AORT)’s stock price reached a new 52-week high on Tuesday . The company traded as high as $21.90 and last traded at $21.59, with a volume of 4555 shares trading hands. The stock had previously closed at $21.64.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on AORT shares. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price target on shares of Artivion in a research report on Monday. Stifel Nicolaus increased their price target on Artivion from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 16th.

Artivion Price Performance

The stock has a market capitalization of $884.98 million, a price-to-earnings ratio of -28.64 and a beta of 1.67. The company has a current ratio of 4.85, a quick ratio of 3.43 and a debt-to-equity ratio of 1.10. The stock has a 50-day simple moving average of $19.52 and a 200 day simple moving average of $17.30.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.24. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. The firm had revenue of $93.67 million during the quarter, compared to analyst estimates of $89.75 million. On average, equities research analysts forecast that Artivion, Inc. will post 0.26 EPS for the current fiscal year.

Insider Transactions at Artivion

In other news, VP Rochelle L. Maney sold 2,315 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $20.27, for a total transaction of $46,925.05. Following the completion of the sale, the vice president now directly owns 39,197 shares of the company’s stock, valued at approximately $794,523.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP Rochelle L. Maney sold 2,315 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $20.27, for a total value of $46,925.05. Following the transaction, the vice president now directly owns 39,197 shares of the company’s stock, valued at approximately $794,523.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James P. Mackin sold 72,069 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $18.85, for a total value of $1,358,500.65. Following the completion of the transaction, the chief executive officer now directly owns 539,036 shares in the company, valued at $10,160,828.60. The disclosure for this sale can be found here. Insiders sold 149,952 shares of company stock valued at $2,891,627 in the last three months. Corporate insiders own 6.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Exchange Traded Concepts LLC bought a new position in shares of Artivion in the 4th quarter valued at approximately $916,000. Algert Global LLC bought a new position in Artivion in the 3rd quarter worth approximately $566,000. GSA Capital Partners LLP increased its position in Artivion by 187.5% in the 3rd quarter. GSA Capital Partners LLP now owns 82,449 shares of the company’s stock worth $1,250,000 after buying an additional 53,773 shares during the period. First Eagle Investment Management LLC increased its position in Artivion by 37.3% in the 3rd quarter. First Eagle Investment Management LLC now owns 526,528 shares of the company’s stock worth $7,982,000 after buying an additional 143,146 shares during the period. Finally, Essex Investment Management Co. LLC bought a new position in Artivion in the 3rd quarter worth approximately $1,034,000. 86.37% of the stock is owned by institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.